Cyclooxygenase 2: A molecular target for cancer prevention and treatment

Kotha Subbaramaiah, Andrew J. Dannenberg

Research output: Contribution to journalReview articlepeer-review

615 Scopus citations


Cyclooxygenase2 (COX-2), an inducible prostaglandin G/H synthase, is overexpressed in several human cancers. Here, the potential utility of selective COX-2 inhibitors in the prevention and treatment of cancer is considered. The mechanisms by which COX-2 levels increase in cancers, key data that indicate a causal link between increased COX-2 activity and tumorigenesis, and possible mechanisms of action of COX-2 are discussed. In a proof-of-principle clinical trial, treatment with the selective COX-2 inhibitor celecoxib reduced the number of colorectal polyps in patients with familial adenomatous polyposis. Selective COX-2 inhibitors appear to be sufficiently safe to permit large-scale clinical testing and numerous clinical trials are currently under way to determine whether selective inhibitors of COX-2 are effective in the prevention and treatment of cancer.

Original languageEnglish (US)
Pages (from-to)96-102
Number of pages7
JournalTrends in Pharmacological Sciences
Issue number2
StatePublished - Feb 1 2003

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Cyclooxygenase 2: A molecular target for cancer prevention and treatment'. Together they form a unique fingerprint.

Cite this